Detection of pyrazinamide resistance among multidrug resistant tuberculosis in North Karnataka
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250972Keywords:
DST, MDR, North Karnataka, PyrazinamideAbstract
Background: Pyrazinamide was identified as a result of a structural activity connection with nicotinamide, which exhibits antitubercular properties (PZA). PZA possesses the exceptional capacity to be directly identified in vivo, first in Mycobacterium TB-infected mice and guinea pigs and subsequently in clinical settings. Pyrazinamide (PZA) is a newly developed antituberculosis (anti-TB) medication that is necessary to shorten the duration of TB treatment. Drug-resistant and drug-susceptible TB, including multidrug-resistant TB, require PZA as part of any therapy regimen because it eliminates nonreplicating persisters that other TB treatments are unable to.
Methods: All clinical specimens presented to the centre for follow-up or for newly diagnosed cases requiring programmatic treatment of DRTB were included in the research. Salivary or insufficient samples, as well as samples that satisfied the centre’s SOP rejection criteria, were excluded from the research. MGIT-based susceptibility testing was used to evaluate the PZA susceptibility for 609 isolates.
Results: Of the 11104 samples, 207 (1.8%) were identified as MDR, 101 (0.9%) as mono-rifampicin resistant, and 619 (5.5%) as mono-isoniazid resistant. The BACTECTM MGITTM 960 technique was then used to cultivate 609 samples. The Bioline TB Ag MPT64 test is a quick way to find the M. tuberculosis complex. PZA susceptibility for 609 isolates was assessed using MGIT-based susceptibility testing. PZA resistance was detected in 194 (31.8%) of the 609 isolates.
Conclusions: The results may emphasise the necessity of regular DST for PZA in Indian public health labs and more study to better identify the variables linked to PZA resistance. In order to inform evidence-based approaches for tuberculosis control and care, this study also highlights the significance of ongoing surveillance of medication resistance patterns.
Metrics
References
Kushner S, Dalalian H, Sanjurjo JL, Bach Jr FL, Safir SR, Smith Jr VK, et al. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J Am Chem Soc. 1952;74(14):3617-21. DOI: https://doi.org/10.1021/ja01134a045
Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(10):5186-93. DOI: https://doi.org/10.1128/AAC.05385-11
Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2014;2(4):10-128.
Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2013;2:1-12. DOI: https://doi.org/10.1128/microbiolspec.MGM2-0023-2013
Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv Med Sci. 2016;61:63-71. DOI: https://doi.org/10.1016/j.advms.2015.09.007
Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuber Lung Dis. 2003;7:6-21
Tam KK, Leung KS, Siu GK, Chang KC, Wong SS, Ho PL, et al. Direct detection of pyrazinamide resistance in Mycobacterium tuberculosis by use of pncA PCR sequencing. J Clin Microbiol. 2019;57(8):10-128. DOI: https://doi.org/10.1128/JCM.00145-19
WHO. Global tuberculosis report 2020. Available from: https://www.iom.int/sites/g/files/tmzbdl486/ files/documents/Global-TB-Report-2020.pdf. Accessed on 2 August 2024.
WHO. Global Tuberculosis Report 2019. Available from: https://www.who.int/publications/i/item/ 9789241565714. Accessed on 2 August 2024.
Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830-43. DOI: https://doi.org/10.1016/S0140-6736(10)60410-2
Abdul Azeem TA, Krishna Karthik MVS KC, Sharath BN. Pyrazinamide resistance among multi drug resistant tuberculosis patients in Karnataka: cross sectional study from a referral centre. J Pulmonol Res Rep. 2023;151:2-4.
Shi J, Su R, Zheng D, Zhu Y, Ma X, Wang S, et al. Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929-41. DOI: https://doi.org/10.2147/IDR.S260161
Thuansuwan W, Chuchottaworn C, Nakajima C, Suzuki Y, Chaichanawongsaroj N. Biphasic medium using nicotinamide for detection of pyrazinamide resistance in Mycobacterium tuberculosis. Antibiotics. 2024;13(6):563. DOI: https://doi.org/10.3390/antibiotics13060563
Becton, Dickinson and Company. BD BACTEC™ MGIT™ 960 PZA kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Package insert L005686JAA(01) 2014-03. Becton, Dickinson and Company, Sparks, MD; 2019.
Kushner S, Dalalian H, Cassell RT, Sanjurjo JL, McKenzie D, Subbarow Y. Experimental chemotherapy of tuberculosis. I. Substituted nicotinamides. J Organic Chem. 1948;13(6):834-6. DOI: https://doi.org/10.1021/jo01164a008
Budzik JM, Jarlsberg LG, Higashi J, Grinsdale J, Hopewell PC, Kato-Maeda M, Nahid P. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. PLoS One. 2014;9(4):e95645. DOI: https://doi.org/10.1371/journal.pone.0095645
Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50(6). DOI: https://doi.org/10.1183/13993003.01354-2017
Xia Q, Zhao LL, Li F, Fan YM, Chen YY, Wu BB, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrugresistant mycobacterium tuberculosis isolates in Zhejiang, China. Antimicro Agents Chemother 2015;59:1690-5. DOI: https://doi.org/10.1128/AAC.04541-14
Gu Y, Yu X, Jiang G, Wang X, Ma Y, Li Y, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84:207-11. DOI: https://doi.org/10.1016/j.diagmicrobio.2015.10.017
Downloads
Published
How to Cite
Issue
Section
